Artiva Biotherapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) had its price target lowered by analysts at Cantor Fitzgerald from $23.00 to $20.00. They now have an "overweight" rating on the stock.
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $18.00 price target on the stock.
Artiva Biotherapeutics, Inc. (NASDAQ: ARTV) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.